Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis

The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.

Women scratch the itch with hand , Concept with Healthcare And Medicine. - Image — Abrocitinib appears to rapidly reduce itching, a hallmark of AD. • Source: Shutterstock

Pfizer Inc. has expanded on the long lead it had with Xeljanz (tofacitinib) over competing Janus kinase (JAK) inhibitors by engineering more selective next-generation drugs in this class, including abrocitinib, for which the company presented the first detailed Phase III atopic dermatitis (AD) data on 12 October in a late-breakers session at the European Academy of Dermatology and Venereology (EADV) meeting in Madrid.

Positive top-line results already have been reported for abrocitinib, a selective inhibitor of JAK1, in two out of three Phase...